These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 9031453

  • 21. Effect of Ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia.
    Simpson IA, Lorimer AR, Walker ID, Davidson JF.
    Thromb Haemost; 1985 Aug 30; 54(2):442-4. PubMed ID: 4082082
    [Abstract] [Full Text] [Related]

  • 22. Effects of vitamin E and gemfibrozil on lipid profiles, lipid peroxidation and antioxidant status in the elderly and young hyperlipidemic subjects.
    Sutken E, Inal M, Ozdemir F.
    Saudi Med J; 2006 Apr 30; 27(4):453-9. PubMed ID: 16598319
    [Abstract] [Full Text] [Related]

  • 23. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability.
    O'Neal DN, O'Brien RC, Timmins KL, Grieve GD, Lau KP, Nicholson GC, Kotowicz MA, Best JD.
    Diabet Med; 1998 Oct 30; 15(10):870-7. PubMed ID: 9796889
    [Abstract] [Full Text] [Related]

  • 24. Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives.
    Kamaliah MD, Sanjay LD.
    Singapore Med J; 2001 Aug 30; 42(8):368-72. PubMed ID: 11764054
    [Abstract] [Full Text] [Related]

  • 25. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy.
    de Maat MP, Madsen JS, Langdahl B, Bladbjerg EM, Tofteng CL, Abrahamsen B, Rejnmark L, Brixen K, Christensen K, Jespersen J, Kristensen SR.
    Thromb Haemost; 2007 Feb 30; 97(2):234-9. PubMed ID: 17264952
    [Abstract] [Full Text] [Related]

  • 26. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
    Dobiásová M, Frohlich J.
    Vnitr Lek; 2000 Mar 30; 46(3):152-6. PubMed ID: 11048517
    [Abstract] [Full Text] [Related]

  • 27. Effect of simvastatin and fluvastatin on plasma fibrinogen levels in patients with primary hypercholesterolemia.
    Okopień B, Krysiak R, Madej A, Belowski D, Zieliński M, Kowalski J, Herman ZS.
    Pol J Pharmacol; 2004 Mar 30; 56(6):781-7. PubMed ID: 15662091
    [Abstract] [Full Text] [Related]

  • 28. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW.
    Curr Med Res Opin; 2001 Mar 30; 17(1):60-73. PubMed ID: 11464448
    [Abstract] [Full Text] [Related]

  • 29. [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
    Gajdos M, Fedelesova V, Mongiellova V, Cibulova L, Huttova D, Polak F, Krivosikova Z.
    Bratisl Lek Listy; 1999 Aug 30; 100(8):449-53. PubMed ID: 10645034
    [Abstract] [Full Text] [Related]

  • 30. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
    Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC.
    Am J Kidney Dis; 2004 Nov 30; 44(5):832-9. PubMed ID: 15492949
    [Abstract] [Full Text] [Related]

  • 31. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
    Gajdos M, Mongiellová V, Huttová D, Cibulová L, Krivosíková Z, Spustová V, Dzúrik R.
    J Cardiovasc Pharmacol; 2001 Nov 30; 38(5):651-6. PubMed ID: 11602811
    [Abstract] [Full Text] [Related]

  • 32. The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia.
    Kovács I, Toldy E, Abel T, Tarján J, Császár A.
    Endothelium; 2005 Nov 30; 12(4):179-83. PubMed ID: 16162440
    [Abstract] [Full Text] [Related]

  • 33. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M, Mariani M, Paoletti R.
    Thromb Haemost; 2000 Apr 30; 83(4):549-53. PubMed ID: 10780315
    [Abstract] [Full Text] [Related]

  • 34. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
    Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Dzavik V, Fruchart JC, Fiévet C, Lefebvre P, Staels B.
    Arterioscler Thromb Vasc Biol; 2005 Mar 30; 25(3):585-91. PubMed ID: 15618549
    [Abstract] [Full Text] [Related]

  • 35. Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure.
    Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK.
    Clin Nephrol; 1996 Jun 30; 45(6):386-9. PubMed ID: 8793231
    [Abstract] [Full Text] [Related]

  • 36. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
    Melenovsky V, Stulc T, Kozich V, Grauova B, Krijt J, Wichterle D, Haas T, Malik J, Hradec J, Ceska R.
    Am Heart J; 2003 Jul 30; 146(1):110. PubMed ID: 12851616
    [Abstract] [Full Text] [Related]

  • 37. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, Kévorkian JP, Guillausseau PJ.
    Eur J Intern Med; 2009 Mar 30; 20(2):197-200. PubMed ID: 19327612
    [Abstract] [Full Text] [Related]

  • 38. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT, Staffa JA, Parks M, Green L.
    Pharmacoepidemiol Drug Saf; 2004 Jul 30; 13(7):417-26. PubMed ID: 15269925
    [Abstract] [Full Text] [Related]

  • 39. [A trial of the use of the hypolipidemic preparation Lipanor (ciprofibrate) in patients with primary hyperlipidemia].
    Kukharchuk VV, Rozhkova TA, Kotova LA, Tvorogova MG, Semenova OA.
    Ter Arkh; 1996 Jul 30; 68(6):58-61. PubMed ID: 8771689
    [Abstract] [Full Text] [Related]

  • 40. [Safety of ciprofibrate. Open study in a Portuguese population].
    Branco MC, de Moura JP, Pereira M, Jesus LC, Ferraz A, Silva JM, Ferreira MR, Serra e Silva P.
    Rev Port Cardiol; 1995 May 30; 14(5):395-9, 360. PubMed ID: 7654400
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.